Given the ongoing emerging evidence of SGLT-2 inhibitors related to the management of HF since their approval, our objectives for this review are to describe and explore the evidence that supports the use of Food and Drug Administration (FDA)-approved SGLT-2 inhibitors in HF patients, empagliflozin and dapagliflozin, and to discuss the role of pharmacists in the early initiation of SGLT-2 inhibitors as part of the GDMT in HF patients. This evidence concerns the gene SLC5A2 and hydrops fetalis.